One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents

OBJECTIVE: Retrospective, real-world study to evaluate visual acuity (VA), anti-vascular endothelial growth factor (anti-VEGF) injection intervals, and central macular thickness (CMT) in neovascular age-related macular degeneration (nAMD) eyes switched to brolucizumab only or to brolucizumab alterna...

Descripción completa

Detalles Bibliográficos
Autores principales: Coney, Joseph M, McCoy, Jasmyne E, Buxy Sinha, Samriddhi, Sonbolian, Nina, Zhou, Lujia, Hull, Thomas P, Lewis, Shawn A, Miller, David G, Novak, Michael A, Pendergast, Scott D, Pham, Hang, Platt, Sean M, Rao, Llewelyn J, Schartman, Jerome P, Singerman, Lawrence J, Donkor, Richard, Fink, Margaret, Zubricky, Ryan, Karcher, Helene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680460/
https://www.ncbi.nlm.nih.gov/pubmed/38026599
http://dx.doi.org/10.2147/OPTH.S432957

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680460/
https://www.ncbi.nlm.nih.gov/pubmed/38026599
http://dx.doi.org/10.2147/OPTH.S432957

Ejemplares similares